World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
44068
World Ranking
14368
National Ranking
8

Overview

Eva Havrdova is affiliated with Charles University in the Czech Republic and has contributed extensively to the field of medicine, with a primary focus on multiple sclerosis research and related neurological disorders. Their work spans over several years and includes a substantial number of scientific publications and collaborations within the medical community.

Their research covers a range of topics, predominantly:

  • Multiple Sclerosis Research Studies
  • Peripheral Neuropathies and Disorders
  • Polyomavirus and related diseases
  • Rheumatoid Arthritis Research and Therapies
  • Systemic Lupus Erythematosus Research
  • Acute Lymphoblastic Leukemia research
  • Autoimmune and Inflammatory Disorders Research

The main fields of study include medicine with an emphasis on pathology and forensic medicine, neurology, oncology, rheumatology, and immunology. This multidisciplinary approach is reflected in their publication record and topics of investigation.

Eva Havrdova has authored or co-authored numerous papers, including notable recent publications such as:

  • "Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study" (2020) published in The Lancet Neurology
  • "Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study" (2021) published in JAMA Neurology
  • "The potential of serum neurofilament as biomarker for multiple sclerosis" (2021) published in Brain
  • "Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis" (2020) published in Multiple Sclerosis Journal
  • "Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis" (2021) published in Journal of Neurology

Their frequent co-authors indicate a collaborative research network within the neurological and multiple sclerosis research communities and include:

  • Dana Horáková
  • Tomáš Kalinčík
  • Helmut Butzkueven
  • Jeannette Lechner-Scott
  • Serkan Özakbaş

Eva Havrdova's work is frequently published in established scientific journals, with the most frequent venues being:

  • Neurology
  • Multiple Sclerosis and Related Disorders
  • Multiple Sclerosis Journal
  • Journal of Neurology Neurosurgery & Psychiatry
  • JAMA Neurology

Best Publications

  • Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

    Chris H Polman;Stephen C Reingold;Brenda Banwell;Michel Clanet

  • A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

    Chris H. Polman;Eva Havrdova;Michael Hutchinson;Ludwig Kappos

  • Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

    Robert J Fox;David H Miller;J Theodore Phillips;Michael Hutchinson

  • Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

    Jeffrey A. Cohen;Alasdair J. Coles;Douglas L. Arnold;Christian Confavreux

  • Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial

    Alasdair J. Coles;Cary L. Twyman;Douglas L. Arnold;Jeffrey A. Cohen

  • ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

    X. Montalban;R. Gold;A. J. Thompson;S. Otero‐Romero

  • Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

    Ludwig Kappos;Ralf Gold;David H Miller;David G MacManus

  • Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis

    J. William L. Brown;J. William L. Brown;J. William L. Brown;Alasdair Coles;Dana Horakova;Eva Havrdova

  • Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

    Ludwig Kappos;David Bates;Gilles Edan;Mefkûre Eraksoy

  • Defining secondary progressive multiple sclerosis.

    Johannes Lorscheider;Johannes Lorscheider;Katherine Buzzard;Katherine Buzzard;Katherine Buzzard;Vilija G Jokubaitis;Vilija G Jokubaitis;Tim Spelman

  • Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

    Eva Havrdova;Steven Galetta;Michael Hutchinson;Dusan Stefoski

  • Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.

    Anna He;Bernd Merkel;James William L Brown;James William L Brown;James William L Brown;Lana Zhovits Ryerson

  • The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL

    P. A. Calabresi;G. Giovannoni;C. Confavreux;S. L. Galetta

  • MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

    D. H. Miller;D. Soon;K. T. Fernando;D. G. MacManus

  • Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

    G Giancarlo Comi;A. Pulizzi;Marco Rovaris;O. Abramsky

  • Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study

    Elena H. Martinez-Lapiscina;Sam Arnow;James A. Wilson;Shiv Saidha

  • Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.

    A.S. Fassas;J. R. Passweg;A. Anagnostopoulos;A. Kazis

  • Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study

    J. Kuhle;G. Disanto;R. Dobson;R. Adiutori

  • Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

    Per Soelberg Sorensen;Steen Lisby;Richard Grove;Frederick Derosier

  • Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

    Ralf Gold;Gavin Giovannoni;Krzysztof Selmaj;Eva Havrdova

Frequent Co-Authors

Krzysztof Selmaj
Krzysztof Selmaj University of Warmia and Mazury in Olsztyn
Gavin Giovannoni
Gavin Giovannoni Queen Mary University of London
Helmut Butzkueven
Helmut Butzkueven Monash University
Douglas L. Arnold
Douglas L. Arnold Montreal Neurological Institute and Hospital
Ludwig Kappos
Ludwig Kappos University Hospital of Basel
Hans-Peter Hartung
Hans-Peter Hartung Heinrich Heine University Düsseldorf
Maria Trojano
Maria Trojano University of Bari Aldo Moro
Robert Zivadinov
Robert Zivadinov University at Buffalo, State University of New York
Xavier Montalban
Xavier Montalban Autonomous University of Barcelona
Raymond Hupperts
Raymond Hupperts Maastricht University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean attending medical school. There are several accelerated healthcare administration degree programs online, ideal for those seeking healthcare leadership roles without investing years in education.

Nursing professionals can advance quickly by enrolling in adn to np programs online. These bridge programs help registered nurses with an associate degree move seamlessly into becoming nurse practitioners.

For those interested in wellness and preventive care, an online degree nutrition provides the knowledge needed for careers in dietetics, public health, and health education.

Aspiring healthcare managers can prepare for high-level roles by choosing online mha programs. Many of these programs are CAHME-accredited, ensuring quality and recognition in the field.

Whether your path is clinical or administrative, these online degrees offer flexible options for building a rewarding healthcare career.

Best Scientists Citing Eva Havrdova

Trending Scientists